You are now leaving the ViiV Healthcare website and being re-directed to an external website
Explore ViiV Healthcare
Learn more about our latest approval
Read More about Our AIDS2020 Panel Discussion
As the only company solely focused on HIV, we go beyond developing new medicines. We take a holistic approach to HIV by developing and supporting sustainable community programs — with and for the HIV community.
ViiV Healthcare has a long-standing commitment to activities that deliver education, treatment and prevention and access to care through on-the-ground programs.
The voice of the HIV community informs everything we do to improve the lives and health outcomes of all people living with HIV.
ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices
Read all news
We must stand together to reduce disparities in communities disproportionately impacted by HIV, with the goal of leaving no person living with HIV behind.
Read how to report a side effect.
Website images are not intended to imply that the models pictured have HIV.
©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.
Connect with us